Skip to content

Tarsus Pharmaceuticals, Inc. TARS Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

AbbVie logo
AbbVieABBV
HRO
HarrowHROW
Glaukos logo
GlaukosGKOS
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s amortization of capitalized software and acquired intangible assets?
Tarsus Pharmaceuticals, Inc. (TARS) reported amortization of capitalized software and acquired intangible assets of $240K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s amortization of capitalized software and acquired intangible assets changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s amortization of capitalized software and acquired intangible assets decreased by 0.0% year-over-year, from $240K to $240K.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s amortization of capitalized software and acquired intangible assets?
Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s amortization of capitalized software and acquired intangible assets has grown at a 196.8% compound annual growth rate (CAGR), from $100K to $881K.